{
  "docId": "019de076-b279-75da-94b2-8ad8944b7652",
  "docSlug": "3080df08d7a75d95f523d4df26f037ae",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 29,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b279-75da-94b2-8ad8944b7652/26",
  "deckHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652",
  "deckJsonHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652.json",
  "deckAnchorHref": "/decks/019de076-b279-75da-94b2-8ad8944b7652#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.32,
        "x": 0.66,
        "y": 0.0062
      },
      "kind": "callout",
      "text": "These results highlight and validate the unique capabilities of the LNC platform beyond MAT2203: 1) Oral delivery, 2) Delivery of active therapeutics to diseased tissues outside the liver, 3) Low blood levels of active drug, with potential for improved safety",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb0e347b-1a58-4f61-bf5a-c9e7039b9a7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.95,
        "x": 0.024,
        "y": 0.003
      },
      "kind": "list",
      "text": "Successful in vivo oral delivery of LNC formulations of 2 different RNAi oligonucleotides targeting inflammatory cytokines; Documented biological activity and therapeutic impact in two different disease models: Psoriasis (IL-17A) and Colitis (TNFa)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d749233-073b-4dcc-82f7-ea33281b7037",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.95,
        "x": 0.024,
        "y": 0.0016
      },
      "kind": "list",
      "text": "Successful in vivo oral delivery of LNC-Docetaxel in a melanoma tumor model; Reductions in tumor weight and volume comparable to those seen with IV docetaxel; No adverse effects on body weight or hematologic parameters",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ede5188e-e511-47e5-9bd0-5f5693f72e51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.056,
        "w": 0.41,
        "x": 0.048,
        "y": 0.056
      },
      "kind": "title",
      "text": "Summary of Recent Key Advances",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d2c6603-3d59-42bd-a492-7a1ec275a228",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "3cfc77a0-2f17-4492-b1fb-92a49269e120",
      "evidence": "The slide uses a list/bullet to present key advances, highlighting the unique capabilities of the LNC platform.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 26,
      "beatId": "38b7b373-3b8e-4b44-9aac-939eeb859d2a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "The document outlines recent key advances and near-term milestones",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}